Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies

Sarah Atkins, Fiona He

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.

Original languageEnglish (US)
Pages (from-to)289-309
Number of pages21
JournalInfectious disease clinics of North America
Issue number2
StatePublished - 2019


  • Chemotherapy
  • Infection
  • Malignant hematology
  • Novel agents
  • Targeted therapy

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies'. Together they form a unique fingerprint.

Cite this